# Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

> **NCT01121042** · PHASE3 · COMPLETED · sponsor: **Bayside Health** · enrollment: 85 (actual)

## Conditions studied

- Schizoaffective and Schizophreniform Disorders
- Schizophrenia

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01121042
- **Lead sponsor:** Bayside Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121042, "Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01121042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*